Ratings Navamedic ASA

Equities

NAVA

NO0010205966

Market Closed - Oslo Bors Other stock markets 08:15:00 10/05/2024 pm IST			5-day change	1st Jan Change
33.1 ^NOK	-0.90%		+1.53%	-9.81%

06/05	Navamedic Rolls Out Erectile Dysfunction Drug in Sweden	MT
30/04	Navamedic ASA Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 54% by 2026.
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

The valuation of the company is particularly high given the cash flows generated by its activity.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
NAVAMEDIC ASA	-9.81%	53.52M	-
ELI LILLY AND COMPANY	+30.38%	695B	C+
NOVO NORDISK A/S	+26.51%	568B	B
JOHNSON & JOHNSON	-4.36%	361B	C+
MERCK & CO., INC.	+19.30%	330B	B-
ABBVIE INC.	+3.73%	283B	C+
ASTRAZENECA PLC	+16.70%	239B	B+
NOVARTIS AG	+8.78%	204B	B-
ROCHE HOLDING AG	-7.93%	198B	A+
AMGEN INC.	+7.68%	168B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes